Using Combinations of Monoclonal Antibodies to Identify Colorectal Tumors
Author Information
Author(s): L.G. Durrant, R.A. Robins, K.C. Ballantyne, R.A. Marksman, J.D. Hardcastle, R.W. Baldwin
Primary Institution: Cancer Research Campaign Laboratories, University of Nottingham
Hypothesis
Can combinations of monoclonal antibodies improve the recognition of colorectal tumor cells compared to single antibodies?
Conclusion
Using combinations of monoclonal antibodies significantly enhances the recognition of colorectal tumors and increases the intensity of staining without binding to normal colon membranes.
Supporting Evidence
- Combinations of antibodies recognized 100% of tumors.
- 60% of tumors bound all four antibodies.
- 78% of tumors bound any three antibodies.
- 90% of tumors bound any two antibodies.
Takeaway
This study shows that using a mix of special antibodies can help doctors find more cancer cells in the intestines without affecting healthy cells.
Methodology
Flow cytometric analysis was used to quantify the binding of monoclonal antibodies to disaggregated colorectal tumor cells.
Limitations
The study primarily focused on a limited number of tumor types and may not represent all colorectal cancers.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website